These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 3471823

  • 1. Interaction of aclarubicin with DNA as compared with daunorubicin and doxorubicin.
    Ando S, Sasada M, Uchino H, Kagawa D, Ueda T, Nakamura T.
    Nihon Gan Chiryo Gakkai Shi; 1986 Dec 20; 21(10):2343-55. PubMed ID: 3471823
    [No Abstract] [Full Text] [Related]

  • 2. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A, Baurain R, Trouet A.
    Cancer Chemother Pharmacol; 1982 Dec 20; 8(2):243-9. PubMed ID: 6955072
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic aspects of aclarubicin with special reference to daunorubicin and doxorubicin.
    Skovsgaard T.
    Eur J Haematol Suppl; 1987 Dec 20; 47():7-20. PubMed ID: 3552720
    [No Abstract] [Full Text] [Related]

  • 4. Cytofluorescence localization of anthracycline antibiotics.
    Egorin MJ, Clawson RE, Cohen JL, Ross LA, Bachur NR.
    Cancer Res; 1980 Dec 20; 40(12):4669-76. PubMed ID: 6934029
    [No Abstract] [Full Text] [Related]

  • 5. DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
    Ando S, Kamiya K, Yoshimura T, Tsutani H, Ueda T, Uchida M, Nakamura T, Uchino H.
    Anticancer Res; 1988 Dec 20; 8(3):409-15. PubMed ID: 3164610
    [Abstract] [Full Text] [Related]

  • 6. [New anthracycline antibiotics and derivatives].
    Tatsuta K.
    Gan To Kagaku Ryoho; 1984 Dec 20; 11(12 Pt 2):2640-52. PubMed ID: 6594977
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia.
    Meriwether WD, Bachur NR.
    Cancer Res; 1972 Jun 20; 32(6):1137-42. PubMed ID: 5030814
    [No Abstract] [Full Text] [Related]

  • 8. Cellular accumulation and disposition of aclacinomycin A.
    Egorin MJ, Clawson RE, Ross LA, Schlossberger NM, Bachur NR.
    Cancer Res; 1979 Nov 20; 39(11):4396-400. PubMed ID: 498071
    [Abstract] [Full Text] [Related]

  • 9. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part I - Antitumor antibiotics and their derivatives.
    Umezawa H.
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan 20; 20(1):12-8. PubMed ID: 6173340
    [Abstract] [Full Text] [Related]

  • 10. The anthracycline antineoplastic drugs.
    Young RC, Ozols RF, Myers CE.
    N Engl J Med; 1981 Jul 16; 305(3):139-53. PubMed ID: 7017406
    [No Abstract] [Full Text] [Related]

  • 11. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K, Kunimoto S, Takeuchi T.
    Biomed Pharmacother; 1987 Jul 16; 41(5):206-13. PubMed ID: 2444279
    [Abstract] [Full Text] [Related]

  • 12. In vitro studies on anthracycline haloderivatives.
    Facchinetti T, Geroni C, Fumagalli A, Giuliani FC.
    Drugs Exp Clin Res; 1986 Jul 16; 12(8):657-61. PubMed ID: 3463498
    [Abstract] [Full Text] [Related]

  • 13. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M.
    Cancer Res; 1989 Nov 01; 49(21):5969-78. PubMed ID: 2551497
    [Abstract] [Full Text] [Related]

  • 14. Anthracycline antibiotic pharmacology and metabolism.
    Bachur NR.
    Cancer Treat Rep; 1979 May 01; 63(5):817-20. PubMed ID: 455323
    [Abstract] [Full Text] [Related]

  • 15. [Effects of aclacinomycin B on biological macromolecular contents and synthesis of L1210 cells].
    Li ZR, Feng JB, Liang F, Zeng SX, Han R.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Jun 01; 6(3):174-8. PubMed ID: 6241042
    [No Abstract] [Full Text] [Related]

  • 16. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW, Raymond V.
    Cancer Treat Rep; 1986 Jan 01; 70(1):51-63. PubMed ID: 2935251
    [No Abstract] [Full Text] [Related]

  • 17. Comparative flavoprotein catalysis of anthracycline antibiotic. Reductive cleavage and oxygen consumption.
    Pan SS, Pedersen L, Bachur NR.
    Mol Pharmacol; 1981 Jan 01; 19(1):184-6. PubMed ID: 6937729
    [No Abstract] [Full Text] [Related]

  • 18. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
    Zenebergh A, Baurain R, Trouet A.
    Eur J Cancer Clin Oncol; 1984 Jan 01; 20(1):115-21. PubMed ID: 6537910
    [Abstract] [Full Text] [Related]

  • 19. Biologic properties of three anthracyclines as a function of lipophilicity.
    Kessel D.
    Biochem Pharmacol; 1979 Oct 01; 28(19):3028-30. PubMed ID: 518699
    [No Abstract] [Full Text] [Related]

  • 20. Failure of aclacinomycin and 7-con-O-methylnogarol (7-OMEN) to decrease cardiac guanylate cyclase activity.
    Levey BA, Ruiz E, Rogerson B, Lehotay DC, Levey GS.
    Cancer Treat Rep; 1980 Oct 01; 64(10-11):1127-8. PubMed ID: 6109566
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.